PI-RADS-Based Segmented Threshold of PSMA-PET SUVmax Is Better than Traditional Fixed Threshold for Diagnosing Clinically Significant Prostate Cancer Especially for PI-RADS 3 Lesions

被引:6
作者
Meng, Xiaoli [1 ]
Ma, Wenhui [1 ]
Zhang, Jingliang [2 ]
Quan, Zhiyong [1 ]
Zhang, Mingru [1 ]
Ye, Jiajun [1 ]
Shu, Jun [3 ]
Ren, Jing [3 ]
Qin, Weijun [2 ]
Kang, Fei [1 ]
Wang, Jing [1 ]
机构
[1] Fourth Mil Med Univ, Xijing Hosp, Dept Nucl Med, Xian, Peoples R China
[2] Fourth Mil Med Univ, Xijing Hosp, Dept Urol, Xian, Peoples R China
[3] Fourth Mil Med Univ, Xijing Hosp, Dept Radiol, Xian, Peoples R China
基金
中国国家自然科学基金;
关键词
Prostate-specific membrane antigen; Positron emission tomography; Multi-parametric MRI; Prostate cancer; GA-68-PSMA PET/CT; MULTIPARAMETRIC MRI; VALIDATION; ACCURACY; BENIGN; TRUS; ISUP;
D O I
10.1007/s11307-023-01841-6
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
ObjectivesOur purpose was to compare the performance of prostate-specific membrane antigen (PSMA)-positron emission tomography (PET) traditional fixed threshold (FT) and newly established Prostate Imaging Reporting and Data System (PI-RADS)-based segmented threshold (ST) for diagnosing clinically significant prostate cancer (csPCa).MethodsThe study retrospectively included 218 patients who underwent multiparametric magnetic resonance imaging (mpMRI) and PSMA-PET examination for suspected prostate cancer (PCa) from January 2018 to November 2021. Lesions with Gleason score & GE; 3 + 4 were diagnosed as csPCa. In PSMA-PET maximum standardized uptake value (SUVmax), the FT for all the lesions and STs for lesions with different PI-RADS score for diagnosing csPCa were determined by receiver operating characteristic (ROC) curves analysis and compared with Z test. The McNemar test was used to compare sensitivity and specificity.ResultsAmong the 218 patients, there were 113 csPCa and 105 non-csPCa. The PSMA-PET FT was SUVmax > 5.3 (area under the curve, AUC = 0.842) and STs for PI-RADS 3/4/5 were SUVmax > 4.2/5.7/6.0 (AUCs = 0.870/0.867/0.882), respectively. The AUC of PSMA-PET ST was higher than that of PSMA-PET FT (0.872 vs. 0.842), especially for PI-RADS 3 (0.870 vs. 0.653). Multimodality diagnostic criteria combining PSMA-PET ST and PI-RADS scores of mpMRI was established and its AUC was higher than that of PSMA-PET ST (0.893 vs. 0.872) and significantly higher than that of PSMA-PET FT (0.893 vs. 0.842) with an improvement in sensitivity (93% vs. 78%, p < 0.05) without significantly sacrificing specificity (86% vs. 91%, p > 0.05).ConclusionsFor diagnosing csPCa, PI-RADS-based PSMA-PET segmented threshold achieved better performance than traditional fixed threshold, especially for PI-RADS 3 lesions. Multimodality diagnostic criteria demonstrated higher diagnostic performance than segmented threshold and significantly better than PSMA-PET fixed threshold for detecting csPCa.
引用
收藏
页码:887 / 896
页数:10
相关论文
共 39 条
[21]   PI-RADS 3 lesions: Does the association of the lesion volume with the prostate-specific antigen density matter in the diagnosis of clinically significant prostate cancer? [J].
Rico, Luis ;
Blas, Leandro ;
Vitagliano, Gonzalo ;
Contreras, Pablo ;
Pita, Hernando Rios ;
Ameri, Carlos .
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2021, 39 (07) :431.e9-431.e13
[22]   Transition zone-based prostate-specific antigen density for differentiating clinically significant prostate cancer in PI-RADS score 3 lesions [J].
Jin, Yongming ;
Chen, Fei ;
Xu, Gang ;
Wei, Chaogang ;
Dong, Congsong .
SCIENTIFIC REPORTS, 2025, 15 (01)
[23]   Magnetic resonance imaging radiomics-based prediction of clinically significant prostate cancer in equivocal PI-RADS 3 lesions in the transitional zone [J].
Zhao, Ying-Ying ;
Xiong, Mei-Lian ;
Liu, Yue-Feng ;
Duan, Li-Juan ;
Chen, Jia-Li ;
Xing, Zhen ;
Lin, Yan-Shun ;
Chen, Tan-Hui .
FRONTIERS IN ONCOLOGY, 2023, 13
[24]   Development and internal validation of PI-RADs v2-based model for clinically significant prostate cancer [J].
Yu Zhang ;
Na Zeng ;
Yi Chen Zhu ;
Yang Xin Rui Huang ;
Qiang Guo ;
Ye Tian .
World Journal of Surgical Oncology, 16
[25]   Development and internal validation of PI-RADs v2-based model for clinically significant prostate cancer [J].
Zhang, Yu ;
Zeng, Na ;
Zhu, Yi Chen ;
Huang, Yang Xin Rui ;
Guo, Qiang ;
Tian, Ye .
WORLD JOURNAL OF SURGICAL ONCOLOGY, 2018, 16
[26]   A nomogram based on PI-RADS v2.1 and clinical indicators for predicting clinically significant prostate cancer in the transition zone [J].
Wei, Chaogang ;
Pan, Peng ;
Chen, Tong ;
Zhang, Yueyue ;
Dai, Guangcheng ;
Tu, Jian ;
Jiang, Zhen ;
Zhao, Wenlu ;
Shen, Junkang .
TRANSLATIONAL ANDROLOGY AND UROLOGY, 2021, 10 (06) :2435-2446
[27]   Transverse prostate maximum sectional area can predict clinically significant prostate cancer in PI-RADS 3 lesions at multiparametric magnetic resonance imaging [J].
Gaudiano, Caterina ;
Braccischi, Lorenzo ;
Taninokuchi Tomassoni, Makoto ;
Paccapelo, Alexandro ;
Bianchi, Lorenzo ;
Corcioni, Beniamino ;
Ciccarese, Federica ;
Schiavina, Riccardo ;
Droghetti, Matteo ;
Giunchi, Francesca ;
Fiorentino, Michelangelo ;
Brunocilla, Eugenio ;
Golfieri, Rita .
FRONTIERS IN ONCOLOGY, 2023, 13
[28]   The function of Prostate Health Index in detecting clinically significant prostate cancer in the PI-RADS 3 population: a multicenter prospective study [J].
Yongheng Zhou ;
Qiang Fu ;
Zhiqiang Shao ;
Wenqiang Qi ;
Minglei Zhong ;
Guangda Lv ;
Zhiwen Jiang ;
Meikai Zhu ;
Wenfu Wang ;
Benkang Shi ;
Shouzhen Chen ;
Yaofeng Zhu .
World Journal of Urology, 2023, 41 :455-461
[29]   MRI Based Radiomics Compared With the PI-RADS V2.1 in the Prediction of Clinically Significant Prostate Cancer: Biparametric vs Multiparametric MRI [J].
Chen, Tong ;
Zhang, Zhiyuan ;
Tan, Shuangxiu ;
Zhang, Yueyue ;
Wei, Chaogang ;
Wang, Shan ;
Zhao, Wenlu ;
Qian, Xusheng ;
Zhou, Zhiyong ;
Shen, Junkang ;
Dai, Yakang ;
Hu, Jisu .
FRONTIERS IN ONCOLOGY, 2022, 11
[30]   Significant Prostate Cancer in Patients with PI-RADS Category 3 Lesions: A Single-Center, Retrospective Cohort Study [J].
Tunc, Burgin ;
Gencturk, Mert ;
Akturk, Adem ;
Kantarci, Fatih .
UROLOGY JOURNAL, 2023, 20 (05) :329-336